This Article Full Text Full Text (PDF) All Versions of this Article: 23/11/2083    most recent 01.ATV.0000096207.01487.36v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deakin, S. Articles by James, R. W. Search for Related Content PubMed PubMed Citation Articles by Deakin, S. Articles by James, R. W. Related Collections Pathophysiology Risk Factors Gene expression Gene regulation Lipid and lipoprotein metabolism Oxidant stress

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:2083.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Simvastatin Modulates Expression of the PON1 Gene and Increases Serum Paraoxonase

A Role for Sterol Regulatory Element–Binding Protein-2

Sara Deakin; Ilia Leviev; Sophie Guernier; Richard W. James

From the Clinical Diabetes Unit, Division of Endocrinology and Diabetes, Medical Faculty, University Hospital, Geneva, Switzerland.

Correspondence to Dr Richard W. James, Division of Endocrinology and Diabetology, University Hospital, 1211 Geneva 14, Switzerland. E-mail Richard.James{at}hcuge.ch

Background— The HDL-associated enzyme paraoxonase protects LDLs from oxidative stress. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) appear to favorably influence the atherosclerotic process by different mechanisms. The present study examined the influence of simvastatin on paraoxonase expression and serum paraoxonase levels.

Methods and Results— Simvastatin upregulated in a dose-dependent manner the activity of the promoter of the paraoxonase gene in expression cassettes transfected into HepG2 cells. Upregulation could be blocked by mevalonate and other intermediates of the cholesterol biosynthetic pathway. Simvastatin increased nuclear factors, notably sterol regulatory element–binding protein-2, capable of binding to the paraoxonase promoter; this was also blocked by mevalonate. Sterol regulatory element–binding protein-2 upregulated promoter activity in vitro. Patients treated with statin showed a significant increase in serum concentrations and activities of paraoxonase.

Conclusions— The data indicate that simvastatin can modulate expression in vitro of the antioxidant enzyme paraoxonase and is associated with increased serum paraoxonase concentration and activity. It is consistent with effects of simvastatin treatment, which have the potential to influence beneficially antiatherogenic mechanisms at the HDL level. The study provides evidence for 1 molecular mechanism by which paraoxonase gene expression could be regulated.

Key Words: lipoproteins • antioxidants • genes • coronary disease • transcription factors

This article has been cited by other articles:

				B. Fuhrman, A. Gantman, J. Khateeb, N. Volkova, S. Horke, J. Kiyan, I. Dumler, and M. Aviram Urokinase activates macrophage PON2 gene transcription via the PI3K/ROS/MEK/SREBP-2 signalling cascade mediated by the PDGFR-{beta} Cardiovasc Res, October 1, 2009; 84(1): 145 - 154. [Abstract] [Full Text] [PDF]

				J. J. Regieli, J. W. Jukema, P. A. Doevendans, A. H. Zwinderman, J. J. Kastelein, D. E. Grobbee, and Y. van der Graaf Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1238 - 1245. [Abstract] [Full Text] [PDF]

				M. V. Poulakou, K. I. Paraskevas, I. S. Vlachos, S.-A. P. Karabina, M. R. Wilson, D. C. Iliopoulos, S. I. Tsitsilonis, D. P. Mikhailidis, and D. N. Perrea Effect of Statins on Serum Apolipoprotein J and Paraoxonase-1 Levels in Patients With Ischemic Heart Disease Undergoing Coronary Angiography Angiology, May 1, 2008; 59(2): 137 - 144. [Abstract] [PDF]

				B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study Clin. Chem., April 1, 2008; 54(4): 738 - 746. [Abstract] [Full Text] [PDF]

				A. -M. Wills, J. E. Landers, H. Zhang, R. J. Richter, A. J. Caraganis, M. E. Cudkowicz, C. E. Furlong, and R. H. Brown Jr Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS Neurology, March 18, 2008; 70(12): 929 - 934. [Abstract] [Full Text] [PDF]

				H. Zhou, K. C. Tan, S. W. Shiu, and Y. Wong Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy Nephrol. Dial. Transplant., March 1, 2008; 23(3): 927 - 933. [Abstract] [Full Text] [PDF]

				I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]

				D. M. Shih, H. R. Kast-Woelbern, J. Wong, Y.-R. Xia, P. A. Edwards, and A. J. Lusis A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids J. Lipid Res., February 1, 2006; 47(2): 384 - 392. [Abstract] [Full Text] [PDF]

				L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]